5-Amino-1MQ reduced excess NNMT activity, which improved how fat cells functioned, lowered inflammation, and enhanced mitochondrial output (which in turn supports better energy use and fat metabolism)
In the phase 2 trial of retatrutide in individuals with T2D and overweight/obesity, retatrutide caused large reductions in circulating amino-acids, although lean mass and physical function were not directly assessed [46]
Orlistat, phentermine/topiramate, naltrexone/bupropion, and the incretin-based drugs liraglutide and semaglutide, both GLP-1 receptor agonists (GLP-1RA), and tirzepatide, a biased dual GIP/GLP-1 receptor agonist, are currently both FDA and EMA approved for the management of non-syndromic obesity 10
Available in 50mg and 100mg vials
There are no preservatives, colours or flavours, and all ingredients are sustainable, human food grade, and quality controlled